Voyager Acquisition II, a blank check company targeting technology, fintech, and healthcare, filed on Friday with the SEC to raise up to $220 million in an initial public offering.
The company plans to raise $220 million by offering 22 million units at a price of $10. Each unit consists of one share of common stock and one-half of one warrant, exercisable at $11.50.
Voyager Acquisition II is led by CEO Adeel Rouf, who previously served as an investment professional at Cohen and Company Asset Management. He is joined by CFO Alex Rogers, who has been a member of the investment team and manages investor relations and communications at Blue Ox Healthcare Partners, and Chairman Warren Hosseinion, the Chairman of Cardio Diagnostics, previous CEO and Director of Clinigence Holdings, and co-founder of Apollo Medical Holdings. The SPAC intends to target businesses in the technology, financial technology, and healthcare industries.
Management's previous SPAC, Voyager Acquisition (VACH; +10% from $10 offer price), has a pending merger agreement with Swiss oncology biotech VERAXA.
The Brooklyn, NY-based company was founded in 2024. It plans to list on the Nasdaq under the symbol VAIIU. Voyager Acquisition II filed confidentially on January 27, 2025. Cantor Fitzgerald is the sole bookrunner on the deal.
